PTX3 and metabolic dysfunction-associated steatotic liver disease: In the current study, we have demonstrated that PTX3 levels in NAFLD patients with fibrosis were higher than NAFLD patients without fibrosis and healthy subjects, independent of metabolic syndrome components.